<p>Dr. Scott Sherr is a Board-Certified Internal Medicine Physician Certified to Practice Health Optimization Medicine (HOMe), a specialist in Hyperbaric Oxygen Therapy (HBOT), and COO of Troscriptions (a Smarter Not Harder company). His clinical telepractice includes HOMe as its foundation alongside an integrative approach to HBOT that includes cutting edge and dynamic HBOT protocols, comprehensive testing (using the HOMe framework), targeted supplementation, personal practices, synergistic technologies (new, ancient, psychedelic), and more.</p><p>Dr. Sherr walks us through how methylene blue has massively evolved from a textile dye into a tool with wide clinical use. He explains its role in supporting mitochondrial processes, its influence on redox cycling, and why he believes low doses can help us manage energy production without strain. We hear how it interacts with neurotransmitters, how it may influence mood, and how it pairs with approaches that shift us out of sympathetic drive. He leads us through dosage considerations, what happens when doses are too high, and when methylene blue becomes useful for infections, travel, or sudden physiological stress. We also explore how Dr. Sherr approaches biomarkers and how he uses methylene blue while assessing deeper issues like inflammation, gut challenges, and chronic immune activation.</p><p><strong>Topics discussed in this episode include:</strong></p><ul><li>How mitochondrial dysfunction links to metabolic stress, toxins, and chronic sympathetic activation.</li><li>How methylene blue concentrates in mitochondria and assists redox cycling during energy production.</li><li>Why reactive oxygen influences inflammation patterns and cellular performance changes.</li><li>How neurotransmitter levels shift through MAOI effects at specific controlled methylene blue doses.</li><li>Cognitive challenges that are linked to mitochondrial strain, gut inflammation, and stress physiology.</li><li>How sympathetic dominance limits healing progress and influences patient response.</li><li>The pairing of methylene blue with neurotherapy approaches to support downregulation processes.</li><li>How dosing considerations change when chronic infections are identified.</li><li>Why higher doses become relevant during acute infections.</li><li>How topical forms or combined peptide formulations expand methylene blue usage across tissues.</li><li>Ways that nitric oxide behavior differs between inducible and endogenous pathways under methylene blue.</li><li>How patient-specific cycling, tolerance, and half-life factors determine dosing patterns.</li><li>How symptom changes at low doses can reveal hidden infections or biofilm disruption events.</li><li>Myths about mitochondrial “over-optimization” or permanent tissue discoloration.</li></ul><p> </p><p>Troscriptions: <a href="https://troscriptions.com/"><u>https://troscriptions.com</u></a> </p><p> </p><p>Troscriptions on YouTube: <a href="https://www.youtube.com/@troscriptions"><u>https://www.youtube.com/@troscriptions</u></a> </p><p> </p><p>Dr. Sherr on Instagram: <a href="https://www.instagram.com/drscottsherr"><u>https://www.instagram.com/drscottsherr</u></a> </p><p> </p><p>Follow our Instagram <a href="https://www.instagram.com/lexiyoonp"><u>https://www.instagram.com/lexiyoonp</u></a> or visit us at <a href="https://www.yoodirecthealth.com/"><u>https://www.yoodirecthealth.com</u></a> </p>